

# COVID-19 UPDATE


## Facts & Figures

Issued August 26, 2021


### Last Contagion Figures

- **August 25: 659,509 7-day average new cases**, compared to 650,547 a week ago and 541,636 a month ago. Now confirmed **213,767,530 cases worldwide** vs 209,150,964 cases last week.
- 4,458,141 people have died (2.1% of confirmed cases) and 190,306,848 have recovered (89.0%).
- **Europe:** 56,367,711 cases; 7-day avg growth of 144,354 vs 139,784 a week ago and 123,379 a month ago.
- **USA:** 38,223,029 cases; 7-day avg growth of 152,480 vs 137,927 a week ago and 61,306 a month ago.
- **Vaccines:** around 5.08 billion doses have been administered globally, of which 365 million in the **USA** and 521 million in the **EU**. 113 vaccines are in clinical evaluation and 184 vaccines are in preclinical evaluation.


**Global Confirmed Cases**




**Global Infected Status**




**Global new cases per day**



**Global New Cases & Deaths**




**daily cases & deaths per million, 7-day avg top 5 european economies\***












\* Overall daily cases and deaths per million people for France, Italy, Spain, Germany and the UK







**People vaccinated ('000)**



**Percentage of people vaccinated**








Country	Cases			Deaths		
	Total	last 7D avg	last month	Total	last 7D avg	last month
USA	38,223,029	+ 152,480	+ 126,798	632,272	+ 1,145	+ 731
India	32,557,767	+ 33,838	+ 36,773	436,396	+ 476	+ 489
Brazil	20,645,537	+ 26,759	+ 30,286	576,730	+ 718	+ 838
Russia	6,804,910	+ 20,205	+ 21,774	178,423	+ 788	+ 794
France	6,673,336	+ 19,993	+ 22,117	113,665	+ 98	+ 69
UK	6,590,747	+ 33,551	+ 29,279	132,003	+ 106	+ 92
Turkey	6,273,681	+ 19,318	+ 21,900	55,212	+ 220	+ 146
Argentina	5,155,079	+ 6,982	+ 9,402	110,966	+ 188	+ 219
Colombia	4,897,150	+ 2,832	+ 5,000	124,474	+ 99	+ 167
Spain	4,815,205	+ 9,950	+ 14,986	83,690	+ 115	+ 82

Country	Cases			Deaths		
	Total	last 7D avg	last month	Total	last 7D avg	last month
Asia	66,724,687	+ 239,258	+ 247,944	1,105,322	+ 5,046	+ 5,132
Europe	56,367,711	+ 144,354	+ 136,334	1,065,762	+ 947	+ 661
North America	46,012,174	+ 196,001	+ 164,491	963,695	+ 2,145	+ 1,521
South America	36,723,143	+ 41,365	+ 49,741	1,124,494	+ 1,189	+ 1,444
Africa	7,691,125	+ 36,367	+ 37,576	192,193	+ 757	+ 879
Oceania	153,260	+ 2,135	+ 1,877	2,024	+ 26	+ 18
Others	723	-	-	15	-	-

\* Regional classification according to the United Nations Geoscheme; Russia included in Asia


### Google Mobility Index: Workplaces

Percentage change from baseline, 7-day avg




### Apple Mobility Index

Percentage change from baseline, 7-day avg



### OpenTable: Seated Diners at Restaurants

change from 2019, 7-day avg



COVID-19 candidate vaccines		
Stage	Phase	N°
Clinical Evaluation	4	8
	3	21
	2/3	10
	2	10
	1/2	26
	1	38
Total Clinical Evaluation		113
Preclinical Evaluation		184

\*Data from the World Health Organization landscape documents

Note: Data sources: WHO, CDC, ECDC, JHU, Worldometers.info, state and national government health departments, local media reports, Google Mobility Report, OpenTable, Bloomberg, Oxford University, OurWorldInData, Harvard Chan school of public health, Al Jazeera. The day is reset after midnight GMT+0. For additional information regarding the data collected and presented in this document please contact [mattia.mammarella@generali-invest.com](mailto:mattia.mammarella@generali-invest.com)

## Main news

- The FDA has given full safety approval to Pfizer and BioNTech’s COVID-19 vaccine in a landmark decision that will allow leading US employers and universities to mandate jobs.
- The US has extended a one-month ban on non-essential travel along the borders with Canada and Mexico to slow the rising spread of COVID-19 despite increasing political pressure to lift the restriction.
- Japan has suspended the use of 1.63 million doses of Moderna COVID-19 vaccine after reports of contamination in several vials.
- Japan is expanding the state of emergency to eight more prefectures (21 prefectures overall) to stem a rapid rise in coronavirus infections.
- Johnson & Johnson (J&J) is saying that a booster shot of its COVID-19 vaccine sharply increases levels of antibodies, according to interim data from two early-stage trials.
- Less than a month into a COVID-19 vaccine booster drive, Israel is seeing signs the country’s high infection and severe illness rates driven by the fast-spreading Delta variant may be slowing down.
- US Vice President Kamala Harris has pledged to provide Vietnam with additional doses of COVID-19 vaccines during a regional visit aimed at countering China’s growing influence.
- Thousands of people have marched in cities across France protesting against the COVID-19 health pass that is now required to access restaurants and cafes, cultural venues, sports arenas and long-distance travel.
- India’s drug regulator has granted emergency use approval for Zydus Cadila’s COVID-19 vaccine, the world’s first DNA shot against the coronavirus, in adults and children aged 12 years and above.

# Imprint

<b>Head of Research</b>	Vincent Chaigneau (vincent.chaigneau@generali-invest.com)	
<b>Head of Macro &amp; Market Research:</b>	Dr. Thomas Hempell, CFA (thomas.hempell@generali-invest.com)	
<b>Team:</b>	Elisabeth Assmuth (elisabeth.assmuth@generali-invest.com) Elisa Belgacem (elisa.belgacem@generali-invest.com) Radomír Jáč (radomir.jac@generali.com) Jakub Krátký (jakub.kratky@generali.com) Michele Morganti (michele.morganti@generali-invest.com) Vladimir Oleinikov, CFA (vladimir.oleinikov@generali-invest.com) Dr. Martin Pohl (martin.pohl@generali.com) Dr. Thorsten Runde (thorsten.runde@generali-invest.com) Dr. Christoph Siepmann (christoph.siepmann@generali-invest.com) Dr. Florian Späte, CIIA (florian.spaete@generali-invest.com) Dr. Martin Wolburg, CIIA (martin.wolburg@generali-invest.com) Paolo Zanghieri, PhD (paolo.zanghieri@generali.com)	
<b>Head of Insurance and AM Research:</b>	Michele Morganti (michele.morganti@generali-invest.com)	
<b>Team:</b>	Raffaella Bagata (raffaella.bagata@generali.com) Alberto Cybo-Ottone, PhD (alberto.cybo@generali.com) Mattia Mammarella (mattia.mammarella@generali-invest.com) Roberto Menegato (roberto.menegato@generali.com) Giovanni Millo, PhD (giovanni.millo@generali.com) Antonio Salera, PhD (antonio.salera@generali.com) Cristiana Settimo (cristiana.settimo@generali.com) Federica Tartara, CFA (federica.tartara@generali.com)	
<b>Issued by:</b>	Generali Insurance Asset Management S.p.A., Research Department	
<b>In Italy:</b> Generali Insurance Asset Management S.p.A Società di gestione del risparmio  Piazza Tre Torri 20145 Milano MI, Italy  Via Niccolò Machiavelli, 4 34132 Trieste TS, Italy	<b>In France:</b> Generali Insurance Asset Management S.p.A Società di gestione del risparmio  2, Rue Pillet-Will 75009 Paris Cedex 09, France	<b>In Germany:</b> Generali Insurance Asset Management S.p.A. Società di gestione del risparmio  Tunisstraße 19-23 50667 Cologne, Germany

[www.generali-investments.com](http://www.generali-investments.com)

This document is based on information and opinions which Generali Insurance Asset Management S.p.A. Società di gestione del risparmio considers as reliable. However, no representation or warranty, expressed or implied, is made that such information or opinions are accurate or complete. Generali Insurance Asset Management S.p.A. Società di gestione del risparmio periodically updating the contents of this document, relieves itself from any responsibility concerning mistakes or omissions and shall not be considered responsible in case of possible changes or losses related to the improper use of the information herein provided. Opinions expressed in this document represent only the judgment of Generali Insurance Asset Management S.p.A. Società di gestione del risparmio and may be subject to any change without notification. They do not constitute an evaluation of any strategy or any investment in financial instruments. This document does not constitute an offer, solicitation or recommendation to buy or to sell financial instruments. Generali Insurance Asset Management S.p.A. Società di gestione del risparmio is not liable for any investment decision based on this document. Generali Investments may have taken, and may in the future take, investment decisions for the portfolios it manages which are contrary to the views expressed herein. Any reproduction, total or partial, of this document is prohibited without prior consent of Generali Insurance Asset Management S.p.A. Società di gestione del risparmio. Generali Investments is part of the Generali Group which was established in 1831 in Trieste as Assicurazioni Generali Austro-Italiache. Generali Investments is a commercial brand of Generali Investments Partners S.p.A. Società di gestione del risparmio, Generali Insurance Asset Management S.p.A. Società di gestione del risparmio, Generali Investments Luxembourg S.A. and Generali Investments Holding S.p.A..